Document text
Final - June 20, 2023
8:00 Welcome & Introductions Dr. Grace Lee (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30 Respiratory Syncytial Virus Vaccines - AdultIntroductionManufacturer presentation: Pfizer season 2 safety & efficacy;
coadministration with influenza vaccine
Manufacturer presentation: GSK season 2 safety & efficacy;
coadministration with influenza vaccine
Updated cost-effectiveness of the Pfizer and GSK vaccines
(main CDC model)
Comparison of cost effectiveness results of the main CDC
model and each manufacturer model (Pfizer & GSK)
Updated EtR (incl. GRADE) and clinical considerations for 2
vaccines (Pfizer & GSK)Dr. Camille Kotton (ACIP, WG Chair)
Dr. Alejandra Gurtman (Pfizer)
Dr. Leonard Friedland (GSK)Dr. David Hutton (University of Michigan)Dr. Ismael Ortega Sanchez (CDC/NCIRD)Dr. Michael Melgar (CDC/NCIRD)
11:45 Break
12:45 Polio Vaccine
Introduction
Recommendations for Adult Polio VaccinationDr. Oliver Brooks (ACIP, WG Chair)Dr. Sarah Kidd (CDC/NCIRD)
2:15 Break
2:30 Influenza Vaccines
IntroductionWG considerations and proposed recommendations Dr. H. Keipp Talbot (ACIP, WG Chair)Dr. Lisa Grohskopf (CDC/NCIRD)
4:00 Break
4:15 Public Comment
4:35 VOTES
RSV Adult Vaccines
Polio VaccineInfluenza Vaccines
VFC VOTEInfluenza VaccinesDr. Michael Melgar (CDC/NCIRD)Dr. Sarah Kidd (CDC/NCIRD)
Dr. Lisa Grohskopf (CDC/NCIRD)
Dr. Jeanne Santoli (CDC/NCIRD)
5:30 AdjournMEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
June 21-23, 2023
Wednesday, June 21, 2023
Final - June 20, 2023
8:00 Welcome & Introductions Dr. Grace Lee (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:35 Agency Updates
CDC, CMS, FDA, HRSA, IHS, OIDP, NIH
8:55 Pneumococcal VaccinesIntroductionEconomic analysis and public health impact of PCV20 use in
children
Comparison of cost-effectiveness analyses on PCV20 use in
children
Summary of WG interpretation on EtR and policy optionsDr. Kathy Poehling (ACIP, WG Chair)
Dr. Charles Stoecker (Tulane University)
Dr. Ayabina Diepreye (CDC/NCIRD)Dr. Miwako Kobayashi (CDC/NCIRD)
10:25 Break
10:40 Dengue Vaccines
IntroductionIntroduction of policy questions for TAK-003Cost effectiveness analysis and health impacts of routine
vaccination with TAK-003 dengue vaccine in Puerto Rico
Summary of two economic models for dengue vaccine TAK-
003 use in Puerto Rico
Partial EtR framework for TAK-003Dr. Wilbur Chen (ACIP, WG Chair)
Dr. Alfonso Hernandez (CDC/NCEZID)Dr. Guido Espana (University of Notre Dame)
Dr. RajReni Kaul (CDC/NCIRD)
Dr. Joshua Wong (CDC/NCEZID)
11:40 Break
12:25 Chikungunya Vaccine
IntroductionValue of chikungunya vaccine to U.S. travelers and providers
Chikungunya virus infection among laboratory workers
Update on large chikungunya outbreak in ParaguayWorkgroup plans and timelines Dr. Beth Bell (ACIP, WG Chair)Ms. Nicole Lindsey (CDC/NCEZID)
Dr. Susan Hills (CDC/NCEZID)
Dr. Susan Hills (CDC/NCEZID)Dr. Susan Hills (CDC/NCEZID)
1:25 Break
1:40 Respiratory Syncytial Virus Vaccines - Pediatric/Maternal
Introduction
Economic analysis of RSVpreF in pediatric populationsEtR Pfizer maternal RSV vaccineEconomic analysis of combined use of nirsevimab and
maternal RSVpreF vaccine
Clinical considerations for RSV maternal vaccine and
nirsevimabDr. Sarah Long (ACIP, WG Chair)
Dr. David Hutton (University of Michigan)Dr. Katherine Fleming-Dutra (CDC/NCIRD)Dr. David Hutton (University of Michigan)
Dr. Jefferson Jones (CDC, NCIRD)
4:40 Break
4:50 Public Comment
5:10 VOTES
Pneumococcal vaccines
VFC VOTE
Pneumococcal VaccinesDr. Jeanne Santoli (CDC/NCIRD)
Dr. Jeanne Santoli (CDC/NCIRD)
5:30 AdjornThursday, June 22, 2023
Final - June 20, 2023
8:00 Welcome & Introductions Dr. Grace Lee (ACIP Chair)
8:10 Mpox Vaccine
IntroductionUpdates From the 2022/2023 U.S. Mpox Outbreak:
Epidemiology, Vaccine Safety, and Vaccine Effectiveness
Use of JYNNEOS During Mpox Outbreaks: Clinical guidance Dr. Pablo Sanchez (ACIP, WG Chair)
Dr. Faisal Minhaj (CDC/NCEZID)
Dr. Agam Rao (CDC/NCEZID)
Considerations for Long-term Protection Against Mpox Dr. Agam Rao (CDC/NCEZID)
10:10 Break
10:20 Meningococcal Vaccines
IntroductionCost effectiveness analysisGRADE/EtRSummary and workgroup considerationsDr. Kathy Poehling (ACIP, WG Chair)Dr. Ismael Ortega-Sanchez (CDC/NCIRD)Dr. Sam Crowe (CDC/NCIRD)Dr. Sam Crowe (CDC/NCIRD)
11:35 Break
11:45 Vaccine SafetyThe childhood immunization schedule and safety: Studies in
the Vaccine Safety Datalink
Preliminary evaluation of aluminum content in childhood
vaccines and risk of asthma in a Danish nationwide cohortDr. Tom Shimabukuro (CDC/NCEZID)
Dr. Matthew Daley (Kaiser Permanente Colorado)
Dr. Anders Hviid (Statens Serum Institut, Copenhagen,
Denmark)
12:30 Break
12:40 COVID-19 Vaccines
Introduction
Updates to COVID-19 epidemiology and vaccine effectiveness
Infection-induced and hybrid immunity
Summary and work group considerationsDr. Matthew Daley (ACIP WG Chair)
Dr. Fiona Havers (CDC/NCIRD), Dr. Romeo Galang
(CDC/NCCDPHP), Dr. Ruth Link-Gelles (CDC/NCIRD)
Dr. Jefferson Jones (CDC/NCIRD)
Dr. Megan Wallace (CDC/NCIRD)
2:40 Adjorn
Acronyms
CDC
CMS Centers for Medicare and Medicaid Services
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE
HRSA Health Resources and Services Administration
IHS Indian Health Service
NCHHSTP
NCIRD
NCEZID
NIAID
OIDP Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
WG Work Group
WHO World Health Organization
VE Vaccine EffectivenessFriday, June 23, 2023
National Institute of Allergy and Infectious DiseasesCenters for Disease Control and Prevention
Grading of Recommendations Assessment, Development and Evaluation
National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
National Center for Immunization & Respiratory Diseases [of CDC/OID]
National Center for Emerging and Zoonotic Diseases [of CDC/OID]